Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Down 18.5% in October

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 79,000 shares, a decrease of 18.5% from the September 30th total of 96,900 shares. Currently, 3.6% of the shares of the company are short sold. Based on an average trading volume of 1,920,000 shares, the short-interest ratio is currently 0.0 days.

Theriva Biologics Stock Up 0.7 %

Shares of NYSEAMERICAN:TOVX traded up $0.01 during trading on Wednesday, reaching $1.48. 99,278 shares of the stock were exchanged, compared to its average volume of 603,169. The stock has a market cap of $3.36 million, a PE ratio of -0.05 and a beta of 1.35. Theriva Biologics has a 12 month low of $1.24 and a 12 month high of $17.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($5.50) EPS for the quarter.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.